Cytokinetics, Incorporated
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cytokinetics, Incorporated (Nasdaq: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating cardiovascular and neuromuscular diseases in which muscle performance is compromised or declining; its lead candidate, aficamten, a next-in-class cardiac myosin inhibitor, advances in Phase 3 clinical trials for obstructive hypertrophic cardiomyopathy (oHCM, including monotherapy versus standard of care), pediatric oHCM, and non-obstructive HCM (nHCM), with additional Phase 2 development for heart failure with preserved ejection fraction (HFpEF) under the name ulacamten (CK-586); omecamtiv mecarbil, a cardiac myosin activator, progresses in Phase 3 for heart failure with reduced ejection fraction (HFrEF); the neuromuscular pipeline features CK-089, a fast skeletal muscle troponin activator, alongside additional skeletal muscle activators in research; and broader muscle biology-directed research targets energetics, growth, and metabolism of muscle. The company, founded in 1997 by pioneers in muscle biology and headquartered in South San Francisco, California, operates primarily in the United States with international partnerships extending to Greater China, Japan, and other regions through strategic alliances. Recent developments include a proposed $550 million private placement of convertible senior notes due 2031 in September 2025 to fund aficamten's potential commercial launch, expanded development, pipeline advancement, and debt refinancing; an expanded royalty financing agreement with Royalty Pharma providing up to $575 million, including $250 million upfront, to support aficamten commercialization and omecamtiv mecarbil's Phase 3 studies; and Sanofi's December 2024 acquisition of Corxel Pharmaceuticals' aficamten rights in Greater China, preserving Cytokinetics' eligibility for up to $150 million in milestones and low-to-high teen royalties on sales there.
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
Cytokinetics to Participate in June Investor Conferences
Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch